Figure 4.
Sites of AR by pre-treatment progressing sites. Donut chart showing sites of AR (LN and/or non-LN sites; outer ring) in patients grouped by pre–PD-1 axis inhibitor sites of progression (LN and/or non-LN sites; inner circle). AR, acquired resistance; PD-1, programmed death 1; LN, lymph node.
